Boehringer Ingelheim Grows Strongly in the UK: Zinta Krumins, Managing Director




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Boehringer Ingelheim Grows Strongly in the UK: Zinta Krumins, Managing Director
Released on: April 15, 2014. © PharmaTelevision Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    In this episode of PharmaTelevision News Review, Fintan Walton talks to Zinta Krumins, Managing Director of Boehringer Ingelheim UK and Ireland
  • Summary
  • Transcript
  • Participants
  • Company
In this episode of PharmaTelevision News Review, Fintan Walton talks to Zinta Krumins, Managing Director of Boehringer Ingelheim UK and Ireland
In this episode of PharmaTelevision News Review, Fintan Walton talks to Zinta Krumins, Managing Director of Boehringer Ingelheim UK and Ireland Zinta explains how Boehringer UK and Ireland have had an exceptional 2013 resulting in sales of over half a billion Euros. They discuss the changes which have had to be made to ensure this success despite tough overall market conditions and how BI will continue to build on this success going forward. They also discuss some of the key successes including SPIRIVA, the company's best selling medicine used to treat chronic obstructive pulmonary disease.
Zinta Krumins
Boehringer Ingelheim
Boehringer Ingelheim
Boehringer Ingelheim GmbH is a pharmaceutical company which concentrates on the development of human pharmaceuticals, biopharmaceuticals, chemicals, and animal health products. The Human Pharmaceuticals sector is the company's largest division, accounting for about 96% of sales. This includes prescription medicines and consumer healthcare products.